Curis — Third Quarter 2026 Earnings Summary

Curis, Inc. reported a net loss of $8.1 million for the third quarter of 2026, with no revenue generated due to the prior sale of Erivedge royalties. The company is currently enrolling patients in two ongoing studies, the TakeAim CLL study and the TakeAim Lymphoma study, which evaluate emavusertib in combination with BTK inhibitors. Clinical data from the TakeAim Lymphoma study showed objective response rates of 100% for BTK-naïve patients and 33% for BTKi-experienced patients as of July 2026. Financially, Curis held $5.0 million in cash and cash equivalents as of September 30, 2026, and expects its existing resources combined with recent private placement proceeds to fund operations into the first quarter of 2027.